GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Oclaro Inc. (OCLR) [hlAlert]

Rating:
Overweight
OCLRD
down 90.21 %

Ocular Sciences, Inc. (OCLR) rated Overweight with price target $1.50 by Thomas Weisel

Posted on: Thursday,  Sep 17, 2009  8:25 AM ET by Thomas Weisel

Thomas Weisel rated Overweight Oclaro Inc. (NASDAQ: OCLR) on 09/17/2009, when the stock price was $28.00. Since
then, Oclaro Inc. has lost 90.21% as of 12/18/2015's recent price of $2.74.
If you would have followed this Thomas Weisel's recommendation on OCLR, you would have lost 90.21% of your investment in 2283 days.

Oclaro, Inc., formerly Bookham, Inc., designs, manufactures and market optical components, modules and subsystems that generate, detect, amplify, combine and separate light signals principally for use in fiber optics communications networks. The Company operates in two business segments: telecom and advanced photonics solutions. Its telecom segment relates to the design, development, manufacture, marketing and sale of optical component products to telecommunications systems vendors. advanced photonics solutions which is focused on the design, manufacture, marketing and sale of optics and photonics solutions for markets including material processing, medical, industrial, printing and biotechnology. It principally sell its transmission and regeneration and optical routing products to telecommunications systems and components vendors, as well as to customers in data communications, military and aerospace.

At Thomas Weisel Partners, the role of Research is to contribute to our clients' decision process in ways that lead to better investment decisions. We cover the key growth sectors of the economy including Consumer, Energy, Financial Services, Healthcare, Internet, Media & Telecom, Metals & Mining and Technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/17/2009 8:25 AM Buy
None
28.00 37.50
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy